Frontage Labs renews deal with Beijing Pharma

USA-based Frontage Laboratories has expanded its R&D agreement with Beijing Pharmaceuticals into the generic drug market.

As part of the deal, Frontage will obtain a newly constructed, 1,800  square-meter R&D center and continued access to Beijing Pharma's  manufacturing areas. The firms will also collaborate to develop 12  Abbreviated New Drug Application products over the next three to five  years, which will be marketed in China, Europe and the USA.

"This partnership demonstrates our continued commitment to support US,  European and Chinese companies' development programs in generic drugs,  and to help them gain access to international markets," said Song Li,  chief executive of Frontage.